Aktuellt
SENASTE
Redeye has revised its estimates in light of Heliospectra’s Q4 2023 report, which was slightly softer than expected regarding sales and order intake. Yet, we expect a rebound in the Dutch market during 2024 and expect Heliospect to capitalise on it with its new product platform. However, due to softer-than-expected order intake in Q4 2023 and seasonal effects, we foresee a softer first half followed by a stronger second half in 2024. Our Base case remains intact at SEK1.4 per share.
LÄS MER
